Company news

Kymera Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

October 15, 2023

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

September 17, 2023

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

August 2, 2023

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

July 26, 2023

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

June 21, 2023

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

June 13, 2023

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

June 8, 2023

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

June 8, 2023

Kymera Therapeutics to Participate in Upcoming June Investor Conference

May 31, 2023

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

May 21, 2023

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

May 18, 2023

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 17, 2023

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

April 10, 2023

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

February 22, 2023

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

January 31, 2023

X-Chem and Kymera Expand Existing Partnership

January 30, 2023

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

January 9, 2023

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

January 3, 2023

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 2, 2023

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

December 13, 2022

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

December 11, 2022

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

December 10, 2022

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

November 30, 2022

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

November 2, 2022

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

November 2, 2022

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

October 19, 2022

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

October 12, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

September 14, 2022

Kymera Therapeutics to Participate in Upcoming September Conferences

August 28, 2022

Kymera Announces $150 Million Private Placement Equity Financing

August 18, 2022

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

August 8, 2022

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

July 26, 2022

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

July 7, 2022

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

June 14, 2022

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

May 31, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

May 31, 2022

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

May 19, 2022

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

May 4, 2022

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

May 2, 2022

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

April 18, 2022

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 7, 2022

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

February 23, 2022

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

January 24, 2022

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

January 17, 2022

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

January 9, 2022

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

January 3, 2022

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

December 15, 2021

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

December 5, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.